 Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Emerging Markets Collaborate to Succeed in Post-Pandemic World

As good scientific investigators, we strive to make our research more reproducible, repeatable, and translatable. These traits are ostensibly engrained in researchers from the start of their careers but often fall to the wayside in pursuit of experimental answers. Throughout this three-episode podcast series, sponsored by The Baker Company, we will weave the common thread of these essential research traits and discuss some ubiquitous techniques common to so many laboratories—focusing on areas that are often overlooked but can have a considerable impact on recapitulating physiological conditions and the efficacy of your experiments. So tune in to this first podcast where we discuss the importance of oxygen biology in common lab experiments. Hosted on Acast. See acast.com/privacy for more information.

As good scientific investigators, we strive to make our research more reproducible, repeatable, and translatable. These traits are ostensibly engrained in researchers from the start of their careers but often fall to the wayside in pursuit of experimental answers. Throughout this three-episode podcast series, sponsored by <a href="https://bakerco.com/" rel="noopener noreferrer nofollow" target="_blank">The Baker Company</a>, we will weave the common thread of these essential research traits and discuss some ubiquitous techniques common to so many laboratories—focusing on areas that are often overlooked but can have a considerable impact on recapitulating physiological conditions and the efficacy of your experiments. So tune in to this first podcast where we discuss the importance of oxygen biology in common lab experiments. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Breathing Oxygen Back into the Biological Conversation

Single-use systems have been steadily climbing toward the top of the tools utilized by biomanufacturers for the commercial-scale production of critical therapeutic products. However, COVID-19 created an inflection point for this technology, generating an even greater demand that will shape the market for many years. Yet, with considerable demand comes the need to focus on the key aspects driving growth while discovering the appropriate solutions to the challenges that invariably arise when technologies are being developed and utilized rapidly.This is our third and final episode of GENcast, where Dr. Ger Brophy, the Executive Vice President of Biopharma Production at Avantor, joins me. We sat down to discuss several essential facets of single-use systems and some ways to help manage risk and decrease the intricacies most often associated with single-use supply chains. Make sure you check out episode one and episode two for more in-depth discussions with Dr. Brophy. Hosted on Acast. See acast.com/privacy for more information.

Single-use systems have been steadily climbing toward the top of the tools utilized by biomanufacturers for the commercial-scale production of critical therapeutic products. However, COVID-19 created an inflection point for this technology, generating an even greater demand that will shape the market for many years. Yet, with considerable demand comes the need to focus on the key aspects driving growth while discovering the appropriate solutions to the challenges that invariably arise when technologies are being developed and utilized rapidly.This is our third and final episode of GENcast, where Dr. Ger Brophy, the Executive Vice President of Biopharma Production at Avantor, joins me. We sat down to discuss several essential facets of single-use systems and some ways to help manage risk and decrease the intricacies most often associated with single-use supply chains. Make sure you check out <a href="https://www.genengnews.com/resources/podcasts/materials-sourcing-precautions-and-improvements-for-cell-and-gene-therapies/" rel="noopener noreferrer nofollow" target="_blank">episode one</a> and <a href="https://www.genengnews.com/resources/podcasts/resins-address-downstream-purification-concerns/" rel="noopener noreferrer nofollow" target="_blank">episode two</a> for more in-depth discussions with Dr. Brophy. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Global Single-Use Network Supports Assurance of Supply

The demand for safe and efficacious biologics has accelerated exponentially in the past several years due to the tremendous success of some of the initial therapeutic offerings in this space. Yet, along with this increased demand comes the need for innovative solutions to improve downstream production workflows. For example, eliminating purification bottlenecks and improving overall yields from chromatography steps can significantly impact the final product’s cost.In this second episode of GENcast with Executive Vice President of Biopharma Production at Avantor, Dr. Ger Brophy, we dive into some of the challenges biomanufacturers face during downstream purification and how addressing the traditional thinking surrounding chromatography resins, and buffers can be highly advantageous and immensely cost-effective. Take a listen to episode 2 below, and if you want to check out episode 1, click here! Hosted on Acast. See acast.com/privacy for more information.

The demand for safe and efficacious biologics has accelerated exponentially in the past several years due to the tremendous success of some of the initial therapeutic offerings in this space. Yet, along with this increased demand comes the need for innovative solutions to improve downstream production workflows. For example, eliminating purification bottlenecks and improving overall yields from chromatography steps can significantly impact the final product’s cost.In this second episode of GENcast with Executive Vice President of Biopharma Production at Avantor, Dr. Ger Brophy, we dive into some of the challenges biomanufacturers face during downstream purification and how addressing the traditional thinking surrounding chromatography resins, and buffers can be highly advantageous and immensely cost-effective. Take a listen to episode 2 below, and if you want to check out episode 1, <a href="https://www.genengnews.com/resources/podcasts/materials-sourcing-precautions-and-improvements-for-cell-and-gene-therapies/" rel="noopener noreferrer nofollow" target="_blank">click here!</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Resins Address Downstream Purification Concerns

The success and applications of cell and gene therapies are seemingly limitless, and economic forecasts project a compound annual growth rate of almost 40% over the next eight years. This rapid expansion is a double edge sword for biomanufacturers of cell and gene therapy products. On the one hand, the tremendous growth is excellent for business. Yet, on the flip side, biomanufacturers are faced with solving the numerous challenges of scaling-up production workflows: from raw material sourcing to supply chain management to adopting new and innovative production modalities. Having a trusted global partner that can help organizations navigate the tumultuous bioprocessing waters of cell and gene therapy production is advantageous and often the key to continued success in the space.In this GENcast, we sit down with the Executive Vice President of Biopharma Production at Avantor, Dr. Ger Brophy, to discuss some of the precautions and improvements for cell and gene therapies and how manufacturers can address many of the challenges they face. Take a listen! Hosted on Acast. See acast.com/privacy for more information.

The success and applications of cell and gene therapies are seemingly limitless, and economic forecasts project a compound annual growth rate of almost 40% over the next eight years. This rapid expansion is a double edge sword for biomanufacturers of cell and gene therapy products. On the one hand, the tremendous growth is excellent for business. Yet, on the flip side, biomanufacturers are faced with solving the numerous challenges of scaling-up production workflows: from raw material sourcing to supply chain management to adopting new and innovative production modalities. Having a trusted global partner that can help organizations navigate the tumultuous bioprocessing waters of cell and gene therapy production is advantageous and often the key to continued success in the space.In this GENcast, we sit down with the Executive Vice President of Biopharma Production at Avantor, Dr. Ger Brophy, to discuss some of the precautions and improvements for cell and gene therapies and how manufacturers can address many of the challenges they face. Take a listen! Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies

This is the final episode in our three-part GENcast series, where we discuss the virtues of mechanistic modeling and how it can significantly impact critical decision-making points in the drug discovery process, especially as drug developers move closer toward the IND process. In our two previous podcasts, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. You can listen to the earlier podcasts with the following links: episode 1, episode 2. In this latest GENcast, I met up once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to discuss the specific applications of mechanistic modeling, especially concerning the process of deciding the first human dose numbers, and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen! Hosted on Acast. See acast.com/privacy for more information.

This is the final episode in our three-part GENcast series, where we discuss the virtues of mechanistic modeling and how it can significantly impact critical decision-making points in the drug discovery process, especially as drug developers move closer toward the IND process. In our two previous podcasts, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. You can listen to the earlier podcasts with the following links: <a href="https://www.genengnews.com/resources/podcasts/gencast-reducing-drug-discovery-and-development-risk-with-mechanistic-modeling/" rel="noopener noreferrer nofollow" target="_blank">episode 1</a>, <a href="https://www.genengnews.com/resources/podcasts/gencast/moving-the-drug-pipeline-forward-with-mechanistic-modeling/" rel="noopener noreferrer nofollow" target="_blank">episode 2</a>. In this latest GENcast, I met up once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to discuss the specific applications of mechanistic modeling, especially concerning the process of deciding the first human dose numbers, and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen! Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development

This is part two in our three-part GENcast series, where we discuss various aspects of the drug discovery and development process and, in particular, how advanced computational techniques like mechanistic modeling can help advance the therapeutic drug pipeline for many developers. In our initial podcast, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. In this latest GENcast, I sat down once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to take a deeper dive into the specific applications of mechanistic modeling and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen! Hosted on Acast. See acast.com/privacy for more information.

This is part two in our three-part GENcast series, where we discuss various aspects of the drug discovery and development process and, in particular, how advanced computational techniques like mechanistic modeling can help advance the therapeutic drug pipeline for many developers. In our <a href="https://www.genengnews.com/resources/podcasts/gencast-reducing-drug-discovery-and-development-risk-with-mechanistic-modeling/" rel="noopener noreferrer nofollow" target="_blank">initial podcast</a>, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. In this latest GENcast, I sat down once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to take a deeper dive into the specific applications of mechanistic modeling and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen! Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Moving the Drug Pipeline Forward with Mechanistic Modeling

The drug discovery and development process can be an arduous endeavor. Manufacturers spend considerable resources and money chasing down potential candidate molecules to create a potential new therapeutic—often resulting in abandoning the candidate in the very later stages of development due to minor factors that might have been overlooked at the onset of the discovery process. Thankfully, there have always been those investigators who sought to merge the fields of mathematics and biology while taking advantage of advanced computing algorithms to help inform and de-risk drug discovery decisions and streamline the development pipeline. This mechanistic modeling approach is helping to transform drug R&amp;D projects by giving pharma and biotech companies the vital information they need to make the critical decisions in a drug’s path toward clinical success.In this GENcast, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully. Jump into the discussion and take a listen! Hosted on Acast. See acast.com/privacy for more information.

The drug discovery and development process can be an arduous endeavor. Manufacturers spend considerable resources and money chasing down potential candidate molecules to create a potential new therapeutic—often resulting in abandoning the candidate in the very later stages of development due to minor factors that might have been overlooked at the onset of the discovery process. Thankfully, there have always been those investigators who sought to merge the fields of mathematics and biology while taking advantage of advanced computing algorithms to help inform and de-risk drug discovery decisions and streamline the development pipeline. This mechanistic modeling approach is helping to transform drug R&amp;D projects by giving pharma and biotech companies the vital information they need to make the critical decisions in a drug’s path toward clinical success.In this GENcast, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully. Jump into the discussion and take a listen! Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Reducing Drug Discovery and Development Risk with Mechanistic Modeling

GEN Biotechnology is the new peer-reviewed journal launching in early 2022 by Mary Ann Liebert Inc. aiming to publish outstanding original research and perspectives across the biotech field. In this Q&amp;A, GEN Biotechnology Senior Editor, Fay Lin, PhD, interviews Editor-in-Chief, Hana El-Samad, PhD, about her scientific research, outreach, and vision for the journal. Learn more about GEN Biotechnology: Website: www.genbiotechjournal.comTwitter: @GENBiotechJrnlSend editorial inquiries to editor@genbiotechjournal.com Hosted on Acast. See acast.com/privacy for more information.

GEN Biotechnology is the new peer-reviewed journal launching in early 2022 by Mary Ann Liebert Inc. aiming to publish outstanding original research and perspectives across the biotech field. In this Q&amp;A, GEN Biotechnology Senior Editor, Fay Lin, PhD, interviews Editor-in-Chief, Hana El-Samad, PhD, about her scientific research, outreach, and vision for the journal. Learn more about GEN Biotechnology: Website: <a href="http://www.genbiotechjournal.com" rel="nofollow" target="_blank">www.genbiotechjournal.com</a>Twitter: @GENBiotechJrnlSend editorial inquiries to editor@genbiotechjournal.com Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Meet the Editor-in-Chief of GEN Biotechnology: Hana El-Samad, PhD

Interrogating the Links between Genetics and Psychiatric Disorders with High Throughput Assays

Genetic Engineering &amp; Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN's unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&amp;D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization.GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies. Hosted on Acast. See acast.com/privacy for more information.

Genetic Engineering &amp; Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN's unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&amp;D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization.GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

GEN Podcasts

GEN Sounds of Science November 29, 2017Canadian team identifies protein that when hindered decreases invasion rate of cancer cells. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science November 29, 2017Canadian team identifies protein that when hindered decreases invasion rate of cancer cells. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Inhibiting Cancer Metastasis

GENcast: Explore, Learn, and Collaborate on Cell &amp; Gene Therapy Manufacturing Challenges by Genetic Engineering and Biotechnology News Hosted on Acast. See acast.com/privacy for more information.

GENcast: Explore, Learn, and Collaborate on Cell &amp; Gene Therapy Manufacturing Challenges by Genetic Engineering and Biotechnology News Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

GENcast: Explore, Learn, and Collaborate on Cell & Gene Therapy Manufacturing Challenges

GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Looking at the CAR-T Landscape As First Approval Nears

GEN Sounds of Science March 9, 2017Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”? Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science March 9, 2017Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”? Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Cancer Immunotherapy: CAR T as 'Car Race'

GEN Sounds of Science March 2, 2017A collaborative team of scientists demonstrates a novel method to deliver safer and more cost-effective therapeutic antibodies, utilizing mRNA.See Article: http://www.nature.com/articles/ncomms14630 Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science March 2, 2017A collaborative team of scientists demonstrates a novel method to deliver safer and more cost-effective therapeutic antibodies, utilizing mRNA.See Article: <a href="http://www.nature.com/articles/ncomms14630" rel="nofollow" target="_blank">http://www.nature.com/articles/ncomms14630</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Turning Patients' Cells into Therapeutic Antibody Factories

GEN Sounds of Science April 14, 2017New research may eventually lead to orally ingestible bacteria for monitoring gut health and disease—with the ultimate goal being the development of a home inflammation test. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science April 14, 2017New research may eventually lead to orally ingestible bacteria for monitoring gut health and disease—with the ultimate goal being the development of a home inflammation test. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Inflammation-Sensing Gut Bacteria Brought to You by Synthetic Biology

GEN Sounds of Science October 23, 2017Researchers discovered that corneal cells isolated from human donors and grown on a dome-shaped surface behaved differently than those on flat one. There are a number of advantages to using such curved substrates. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science October 23, 2017Researchers discovered that corneal cells isolated from human donors and grown on a dome-shaped surface behaved differently than those on flat one. There are a number of advantages to using such curved substrates. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

New Method Developed for Growing Tissue Engineered Corneas

GEN Sounds of Science February 16, 2017Bill Warren, partner with the law firm Eversheds Sutherland and chair of its biotechnology and life sciences team, discusses the ruling by a three-judge panel of the Patent Trial and Appeal Board siding with the Broad Institute of MIT and Harvard in the bitter legal battle over who invented CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science February 16, 2017Bill Warren, partner with the law firm Eversheds Sutherland and chair of its biotechnology and life sciences team, discusses the ruling by a three-judge panel of the Patent Trial and Appeal Board siding with the Broad Institute of MIT and Harvard in the bitter legal battle over who invented CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Sorting Out the CRISPR Patent Case

GEN Sounds of Science February 2, 2017Finding in female mice may also be relevant to certain human psychiatric disorders. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science February 2, 2017Finding in female mice may also be relevant to certain human psychiatric disorders. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

“Sexual Attraction” Neurons in the Brain Discovered

GEN Sounds of Science May 1, 2018GEN recently spoke to Minjun Liu, Ph.D., marketing director for OriGene, for a sponsored podcast. OriGene Technologies was founded as a research tool company focused on the creation of a large commercial collection of full-length human cDNAs in a standard expression vector. Company officials say the firm’s mission is to prepare comprehensive, genome-wide research tools and technology platforms to allow scientists to better study complete biological pathways. The goal is to enable more detailed insights into stem-cell research and into disease mechanisms, such as those that lead to cancer. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science May 1, 2018GEN recently spoke to Minjun Liu, Ph.D., marketing director for OriGene, for a sponsored podcast. OriGene Technologies was founded as a research tool company focused on the creation of a large commercial collection of full-length human cDNAs in a standard expression vector. Company officials say the firm’s mission is to prepare comprehensive, genome-wide research tools and technology platforms to allow scientists to better study complete biological pathways. The goal is to enable more detailed insights into stem-cell research and into disease mechanisms, such as those that lead to cancer. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Lentiviral Systems for Gene Delivery

Great symphonic music starts with the fundamental elements common to all orchestral instruments, but what separates a good symphony from a great one is not just pure talent, but the ability of the musicians to work together to create something ethereal. In most respects, science is no different. The open exchange of ideas and collaborative spirit is how science moves forward to create something impactful for society. And like great instrumentalists, scientists practice their craft every time they step into the laboratory—but even the most talented amongst them requires assistance on occasion.The need for these collaborative scientific environments is most apparent in emerging biotechnology regions like China, where companies are quickly ramping up biomanufacturing processes to become competitive with more established biotech hubs. Scientists at the M Lab™ Collaboration Centers from MilliporeSigma are well versed in supporting scientists and engineers and assisting them with bioprocessing challenges that can make even the most harmonious scientific teams go out of tune. They M Lab Collaboration Centers’ team has the expertise to assist growing companies with manufacturing scale-up questions, provide chromatography support, and offer the latest expertise on single-use bioprocessing systems.We connected recently with a few members of the M Lab Collaboration Centers to discuss some of the recent, successful projects they collaborated on with clients in China. They discuss some of the challenges they faced on their project, how they set out to resolve those issues, and what the future holds for them and the Chinese biopharma market. Listen in to the conversation below. Hosted on Acast. See acast.com/privacy for more information.

Great symphonic music starts with the fundamental elements common to all orchestral instruments, but what separates a good symphony from a great one is not just pure talent, but the ability of the musicians to work together to create something ethereal. In most respects, science is no different. The open exchange of ideas and collaborative spirit is how science moves forward to create something impactful for society. And like great instrumentalists, scientists practice their craft every time they step into the laboratory—but even the most talented amongst them requires assistance on occasion.The need for these collaborative scientific environments is most apparent in emerging biotechnology regions like China, where companies are quickly ramping up biomanufacturing processes to become competitive with more established biotech hubs. Scientists at the M Lab™ Collaboration Centers from MilliporeSigma are well versed in supporting scientists and engineers and assisting them with bioprocessing challenges that can make even the most harmonious scientific teams go out of tune. They M Lab Collaboration Centers’ team has the expertise to assist growing companies with manufacturing scale-up questions, provide chromatography support, and offer the latest expertise on single-use bioprocessing systems.We connected recently with a few members of the M Lab Collaboration Centers to discuss some of the recent, successful projects they collaborated on with clients in China. They discuss some of the challenges they faced on their project, how they set out to resolve those issues, and what the future holds for them and the Chinese biopharma market. Listen in to the conversation below. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

GENcast: Explore, Learn, and Collaborate on Bioprocessing Challenges in China

GENcast  Explore, Learn, &amp; Collaborate On Viral Safety In Biomanufacturing by Genetic Engineering and Biotechnology News Hosted on Acast. See acast.com/privacy for more information.

GENcast Explore, Learn, &amp; Collaborate On Viral Safety In Biomanufacturing by Genetic Engineering and Biotechnology News Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

GENcast  Explore, Learn, & Collaborate On Viral Safety In Biomanufacturing

GEN Sounds of Science July 13, 2017]Findings from a new study published in PLOS Pathogens by investigators at the University of Michigan and the FDA underscores the importance of calcium in Clostridium difficile spore germination.Study Link: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006443 Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science July 13, 2017]Findings from a new study published in PLOS Pathogens by investigators at the University of Michigan and the FDA underscores the importance of calcium in Clostridium difficile spore germination.Study Link: <a href="http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006443" rel="nofollow" target="_blank">http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006443</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Is Calcium the Achilles Heel for Clostridium Infections?

GEN Sounds of Science February 28, 2017Scientists have long written off cannibalism as a strange phenomenon with little biological significance. However, the true nature of cannibalism —the role it plays in evolution as well as human history — is even more intriguing (and more normal) than the misconceptions we’ve come to accept as fact. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science February 28, 2017Scientists have long written off cannibalism as a strange phenomenon with little biological significance. However, the true nature of cannibalism —the role it plays in evolution as well as human history — is even more intriguing (and more normal) than the misconceptions we’ve come to accept as fact. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Cannibalism: A Biological and Evolutionary Perspective

GEN Sounds of Science June 1, 2018CEM Corporation Applies Advanced Microwave TechnologyCEM provides microwave instrumentation for researchers involved in analytical and synthetic chemistry. Major application areas include acid digestion for elemental analysis, compositional testing of food products, peptide synthesis, and chemical synthesis.GEN recently spoke to Michael J. Karney, CEM’s life science product manager. During a sponsored pocast, Mr. Karney described how CEM’s technologies are improving workflows for end users, specifically in the fields of drug design and development. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science June 1, 2018CEM Corporation Applies Advanced Microwave TechnologyCEM provides microwave instrumentation for researchers involved in analytical and synthetic chemistry. Major application areas include acid digestion for elemental analysis, compositional testing of food products, peptide synthesis, and chemical synthesis.GEN recently spoke to Michael J. Karney, CEM’s life science product manager. During a sponsored pocast, Mr. Karney described how CEM’s technologies are improving workflows for end users, specifically in the fields of drug design and development. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Streamlining the Peptide Synthesis Process

GEN Sounds of Science September 15, 2017MilliporeSigma is using is expertise in biomanufacturing to take advantage of the growing interest in continuous or next generation bioprocessing. The company is investing in specific technologies in terms of dedicated teams, focused R&amp;D efforts, and product-development projects.Website: http://www.emdmillipore.com/ Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science September 15, 2017MilliporeSigma is using is expertise in biomanufacturing to take advantage of the growing interest in continuous or next generation bioprocessing. The company is investing in specific technologies in terms of dedicated teams, focused R&amp;D efforts, and product-development projects.Website: <a href="http://www.emdmillipore.com/" rel="nofollow" target="_blank">http://www.emdmillipore.com/</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Millipore Says It is Bullish on Continuous Bioprocessing

GEN Sounds of Science March 16, 2017A recent study suggest that children with sensitive genotypes who come from low-income homes will be less financially successful than their same sex sibling without those genotypes. But children with those same genotypes from a high-income home would actually fare better economically as young adults than their brother or sister. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science March 16, 2017A recent study suggest that children with sensitive genotypes who come from low-income homes will be less financially successful than their same sex sibling without those genotypes. But children with those same genotypes from a high-income home would actually fare better economically as young adults than their brother or sister. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Sensitive Genotypes and their Impact on Economic Success

GEN Sounds of Science May 19, 2017Sara Radcliffe, president and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to impact biopharma, and what the industry hopes he will accomplish as the FDA’s new commissioner. Hosted on Acast. See acast.com/privacy for more information.

GEN Sounds of Science May 19, 2017Sara Radcliffe, president and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to impact biopharma, and what the industry hopes he will accomplish as the FDA’s new commissioner. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

FDA’s New Commissioner Hits the Ground Running

ATCC Podcast Final by Genetic Engineering and Biotechnology News Hosted on Acast. See acast.com/privacy for more information.

ATCC Podcast Final by Genetic Engineering and Biotechnology News Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

ATCC Podcast Final

David Rimm

Nanostring Podcast with David Rimm, MD, PhD by Genetic Engineering and Biotechnology News Hosted on Acast. See acast.com/privacy for more information.

Nanostring Podcast with David Rimm, MD, PhD by Genetic Engineering and Biotechnology News Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Nanostring Podcast with David Rimm, MD, PhD

The best podcast episodes of the most interesting stories and things. From skyping someone while they're in space, to tracking down and meeting a telephone scammer in person, to the story of a Galapagos. These episodes will keep you and all your friends entertained and captivated for hours. Learn something new in every episode! Add episodes you're interested into your queue below!

Best Episodes: Interesting Stories & Things

The best philosophy podcast episodes. Asking questions about how to live a better life, what it means to be and do good, to the idea of God. This topic includes episodes that bring about important questions that everyone should be asking themselves. Add episodes you're interested into your queue below!